Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 23, 2023 - Issue 5
Submit an article Journal homepage
1,279
Views
0
CrossRef citations to date
0
Altmetric
Editorial

What is the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?

Takafumi Yanagisawaa Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;b Department of Urology, The Jikei University School of Medicine, Tokyo, JapanCorrespondence[email protected]
View further author information
,
Manuela Schmidingera Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaView further author information
,
Harun Fajkovica Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;c Karl Landsteiner Institute of Urology and Andrology, Vienna, AustriaView further author information
,
Pierre I. Karakiewiczd Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, CanadaView further author information
,
Takahiro Kimurab Department of Urology, The Jikei University School of Medicine, Tokyo, JapanView further author information
&
Shahrokh F. Shariata Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;c Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria;e Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan;f Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA;g Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic;h Department of Urology, Weill Cornell Medical College, New York, NY, USAView further author information
Pages 455-459 | Received 30 Jan 2023, Accepted 05 Apr 2023, Published online: 13 Apr 2023

References

  • Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82:399–410.
  • Ged Y, Lee CH. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2022;22:1049–1059.
  • Mori K, Mostafaei H, Miura N, et al. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunol Immunother. 2021;70:265–273.
  • Quhal F, Mori K, Bruchbacher A, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2021;4:755–765.
  • Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417–427.
  • Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol. 2021;80:417–424.
  • Chakiryan NH, Gore LR, Reich RR, et al. Survival outcomes associated with cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma. JAMA Netw Open. 2022;5:e2212347.
  • Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2019;5:164–170.
  • Bhindi B, Graham J, Wells JC, et al. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur Urol. 2020;78:615–623.
  • Marchioni M, Kriegmair M, Heck M, et al. Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients with metastatic renal cell carcinoma. results from a multi-institutional registry (REMARCC). Eur Urol Oncol. 2021;4:256–263.
  • McIntosh AG, Umbreit EC, Holland LC, et al. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020;126:3950–3960.
  • Mori K, Quhal F, Yanagisawa T, et al. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta-analysis. Int Immunopharmacol. 2022;108:108720.
  • Choueiri TK, Powles TB, Albiges L, et al. LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Ann Oncol. 2022;33:S1430–1.
  • Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol. 2020;38:e604.9–e604.17.
  • Bakouny Z, El Zarif T, Dudani S, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium. Eur Urol. 2023;83:145–151.
  • Studentova H, Rusarova N, Ondruskova A, et al. The role of cytoreductive nephrectomy in renal cell carcinoma with sarcomatoid histology: a case series and review of the literature. Curr Oncol. 2022;29:5475–5488.
  • Isali I, Braun A, Bukavina L, et al. Role of cytoreductive surgery in the era of immunotherapy. Curr Opin Urol. 2022;32:618–626.
  • Shirotake S, Miyama YU, Baba Y, et al. Impact of cytoreductive nephrectomy following nivolumab plus ipilimumab therapy for patients with advanced renal cell carcinoma. Anticancer Res. 2022;42:2727–2735.
  • Graafland NM, Szabados B, Tanabalan C, et al. Surgical safety of deferred cytoreductive nephrectomy following pretreatment with immune checkpoint inhibitor-based dual combination therapy. Eur Urol Oncol. 2022;5:373–374.
  • Pignot G, Thiery-Vuillemin A, Albigès L, et al. Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma. Eur Urol Oncol. 2022;5:577–584.
  • Meerveld-Eggink A, Graafland N, Wilgenhof S, et al. Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment. Eur Urol Open Sci. 2022;35:54–58.
  • Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: aSCO guideline. J Clin Oncol. 2022;40:2957–2995.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.